1471-0528/asset/BJO_left.gif?v=1&s=0fb87361cdb6be25fdf05019eed6d47f5143f610)
1471-0528/asset/olbannerright.gif?v=1&s=3892ef16ff18d6834c302faf85268a49f5fc588f)
Degradation of radiolabelled arginine vasopressin (125I-AVP) by the human placenta perfused in vitro
Article first published online: 19 AUG 2005
DOI: 10.1111/j.1471-0528.1988.tb12802.x
Issue
1471-0528/asset/cover.gif?v=1&s=b4e1d96c46e18c61210d584b63c13ee375cf562b "BJOG: An International Journal of Obstetrics & Gynaecology")
BJOG: An International Journal of Obstetrics & Gynaecology
Volume 95, Issue 5, pages 488–492, May 1988
Additional Information
How to Cite
LANDON, M. J., COPAS, D. K., SHIELLS, E. A. and DAVISON, J. M. (1988), Degradation of radiolabelled arginine vasopressin (125I-AVP) by the human placenta perfused in vitro. BJOG: An International Journal of Obstetrics & Gynaecology, 95: 488–492. doi: 10.1111/j.1471-0528.1988.tb12802.x
Publication History
- Issue published online: 19 AUG 2005
- Article first published online: 19 AUG 2005
- Received 24 July 1987 Accepted 5 August 1987
- Abstract
- References
- Cited By
Summary. The capacity of the human placenta to degrade 125I-labelled arginine vasopressin (125I-AVP) was studied in vitro using a dual circuit perfused lobule preparation. Seven placentas were perfused with the perfusate on the maternal side of the lobule containing 125I-AVP at the upper limit of the physiological range. On average, over a 30-min period, 48% of the 125I-AVP appeared to have been metabolized. With one exception, a patient whose labour was augmented with intravenous oxytocin, no 125T-AVP apparently crossed the placental lobule to the fetal circulation. These data indicate that the human placenta has a considerable capacity to degrade AVP.